Online inquiry

IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14489MR)

This product GTTS-WQ14489MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CNR1 gene. The antibody can be applied in Non-alcoholic fatty liver disease (NAFLD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001160226.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1268
UniProt ID P21554
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14489MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15327MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ2183MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ13932MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-2810
GTTS-WQ6173MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CP-751871
GTTS-WQ7790MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GS-HIV
GTTS-WQ339MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 1F5
GTTS-WQ13845MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-1193
GTTS-WQ12562MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NV-01
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW